- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04394715
Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID)
Study Overview
Status
Intervention / Treatment
Detailed Description
Cardiovascular disease (CVD) remains the leading cause of death in most developed countries, including the United States. A key risk factor for CVD is an elevation in low-density lipoprotein cholesterol, or LDL-C. Based on favorable results from large clinical trials, guidelines support the use of high intensity statin therapy for the reduction of LDL-C in very high risk patients and addition of non-statin therapies including ezetimibe and PCSK9 inhibitors if the LDL-C remains above 70 mg/dL. However, implementation of these guidelines is poor and there remains substantial underuse of evidence-based lipid lowering therapies across healthcare systems.
Real-time alerting to important clinical conditions, when fired in an appropriate and timely manner, can have positive impacts on patient outcomes through increased physician awareness and adherence to best practices. To this end, this study has been designed to evaluate whether automated electronic alerts built into the Epic electronic health record can improve the management of hyperlipidemia among patients of outpatient internal medicine and cardiology practices within the Yale New Haven Health System who are at very high risk for future atherosclerotic CVD (ASCVD) events.
One hundred physicians will undergo cluster randomization to either the alert group or the control (usual care) group. Upon opening the order entry screen of an eligible patient with hyperlipidemia, the alert group will receive an informational alert that informs the provider that the patient has hyperlipidemia and is at very high risk for future ASCVD events and provides ACC/AHA-guideline-directed actionable items, including a link to a hyperlipidemia "order set" to include both diagnostic and therapeutic options.
The primary outcome will be the proportion of patients who have intensification of their lipid lowering therapy (increase in statin dose or addition of ezetimibe or addition of a PCSK9 inhibitor) at 90-days. The secondary outcomes will be achieved LDL-C at 6-months and proportion of patients with LDL-C levels less than 70 mg/dL and less than 55 mg/dL. In an optional extension phase, long-term exploratory outcomes looking at the rate of major cardiovascular cardiac events (MACE), defined as hospitalization for myocardial infarction, stroke, unstable angina, or coronary or peripheral artery revascularization will be evaluated at 2 years.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Connecticut
-
Bridgeport, Connecticut, United States, 06610
- Bridgeport Hospotal
-
Greenwich, Connecticut, United States, 06830
- Greenwich Hospital
-
New Haven, Connecticut, United States, 06510
- Yale New Haven Hospital
-
New Haven, Connecticut, United States, 06511
- St. Raphael's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria for Patient Subjects:
- Adults 18 years of age or greater
- Currently being seen as an outpatient of Internal Medicine or Cardiology within the Yale New Haven Health System
- At very high risk for ASCVD, defined by a history of a major ASCVD event, and most recent lipid profile with LDL-C greater than 70 mg/dL, with or without other high-risk features (diabetes, CKD, age >65 years)
Exclusion Criteria for Patient Subjects:
- Heart transplant recipient
- Left ventricular assist device recipient
- Hospital inpatient status
Inclusion Criteria for Provider Subjects:
- Practicing at an outpatient cardiology or internal medicine practice with the Yale New Haven Health System
- High frequency of eligible patients seen, based on retrospective review of outpatient records
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Providers will see an electronic alert for eligible patients who are at very high risk for future ASCVD events upon opening of the patient's order entry screen in the medical record.
|
Providers will see an automated electronic alert for each eligible hyperlipidemia patient at high risk for future atherosclerotic CVD events.
This alert will appear when the provider enters the order entry screen in the patient's medical record during the patient's first eligible outpatient visit.
The alert consists of a "pop up" that notifies the physician that the patient is at very high risk for ASCVD events, displays the most recent cholesterol values and the patient's current lipid lowering therapy.
It also includes a link to full treatment guidelines for hyperlipidemia, which includes a continuing medical education (CME) option to obtain CME credits.
|
No Intervention: Control
Providers will not see an electronic alert for any patients and will provide usual care.
Silent alerts will be generated that will be sent to study team members.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with intensification of lipid lowering therapy
Time Frame: 90 days from first alert for any given patient
|
Intensification of lipid lowering therapy is defined as an increase in statin dose, an addition of ezetimibe, or addition of PCSK9.
Any one of the three will be sufficient to meet this endpoint.
Proportion of patients who meet this endpoint will be compared between study arms.
|
90 days from first alert for any given patient
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Achieved LDL-C at 6 months
Time Frame: 6 months from first alert for any given patient
|
LDL-6 at 6 months as measured by medical record review
|
6 months from first alert for any given patient
|
Proportion of patients with an LDL-C of less than 70 mg/dL
Time Frame: 6 months from first alert for any given patient
|
Number of patients with LDL-C levels less than 70 mg/dL based on medical record review.
Number of patients who meet this endpoint will be compared between study arms.
|
6 months from first alert for any given patient
|
Proportion of patients with an LDL-C of less than 55 mg/dL
Time Frame: 6 months from first alert for any given patient
|
Number of patients with LDL-C levels less than 55 mg/dL based on medical record review.
Number of patients who meet this endpoint will be compared between study arms.
|
6 months from first alert for any given patient
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nihar Desai, MD MPH, Yale University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2000027852
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on High Risk Atherosclerotic Cardiovascular Disease
-
AstraZenecaThe Cleveland Clinic; IQVIA RDS Inc.CompletedEligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)United States, Belgium, Italy, Netherlands, Denmark, Taiwan, Poland, Russian Federation, Korea, Republic of, Hungary, United Kingdom, China, New Zealand, Czechia, Australia, South Africa, Ukraine, Japan, Canada, Mexico, Lithuania, Estoni...
-
Novartis PharmaceuticalsCompletedAtherosclerotic Cardiovascular Disease | Atherosclerotic Cardiovascular Disease Risk Equivelents | Elevated Low Density Lipoprotein CholesterolUnited Kingdom
-
Pieter MuntendamIcahn School of Medicine at Mount Sinai; AstraZenecaEnrolling by invitationHeart Diseases | Stroke | Plaque, Atherosclerotic | Cardiovascular Risk Factor | Atherosclerotic DiseaseUnited States
-
Jordan Collaborating Cardiology GroupThe Cardiovascular Academy Group of the JCS; The Jordan Cardiac Society (JCS); Istishari Hospital Department of Clinical ResearchTerminatedAtherosclerotic Cardiovascular Risk | Low-density-lipoprotein (LDL) CholesterolJordan
-
Centre Hospitalier Universitaire DijonTerminatedHigh Cardiovascular Risk Patients | Low Cardiovascular Risk PatientsFrance
-
Centre Hospitalier Universitaire de Saint EtienneTerminatedFirefighter | High Cardiovascular RiskFrance
-
Yonsei UniversityNot yet recruitingHealthy Elderly Individuals With High LDL-cholesterol or Risk of Cardiovascular DiseaseKorea, Republic of
-
Institute for Clinical Effectiveness and Health...Inter-American Development BankUnknownModerate and High Cardiovascular RiskArgentina
-
Jordan Collaborating Cardiology GroupThe Jordan Cardiovascular Research Group JoCVRG; Yarmouk University School...RecruitingCardiovascular Risk FactorsJordan
-
Yonsei UniversityRecruitingHigh Risk Cardiovascular Disease PatientsKorea, Republic of
Clinical Trials on Electronic Alert
-
Guangdong Provincial People's HospitalUnknownAcute Kidney Injury
-
Yale UniversityCompletedRisk EValuation And Its Impact on ClinicAL Decision Making and Outcomes in Heart Failure (REVeAL-HF)Heart FailureUnited States
-
Columbia UniversitySeattle Children's Hospital; New York Presbyterian Hospital; Agency for Healthcare...Completed
-
University of California, DavisCompleted
-
University Hospital Inselspital, BerneCompleted
-
University of Texas Southwestern Medical CenterActive, not recruitingHeart Failure | Diabetes Mellitus, Type 2United States
-
Brigham and Women's HospitalCompletedStroke | Atrial FibrillationUnited States
-
Stanford UniversityCompleted